The collaboration marks a turning point in AI-driven drug design and trial forecasting, de-risking the drug development ...

Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus" or the "Company"), a global leader in model-informed and ...

Learn how AI is transforming predictions of drug-induced liver injury and aiding drug development for safer therapeutics.

By M. Marin OTCQB:AINMF READ THE FULL AINMF RESEARCH REPORT Benefits of NetraMark’s AI de-risking solutions for clinical research NetraMark (OTCQB:AINMF), an AI company developing AI and Machine ...

Medicare costs could decrease under a new proposal from the Trump administration that would shift the drug payment model entirely. The Centers for Medicare & Medicaid Services (CMS) released details ...

Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus" or the "Company"), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced ...

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- Simulations Plus, Inc. (SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances ...

Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced ...

CELT students participated in the Kentucky Retail Survey Project by touring and investigating different tobacco vendors across town. (Photo courtesy Estill Development Alliance) This is your first of ...

Scientists have developed a new artificial intelligence tool that can identify harmful genetic mutations and predict the types of diseases they are likely to cause, offering faster diagnosis and new ...

TORONTO, Dec. 15, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is ...

Please provide your email address to receive an email when new articles are posted on . AIM-MASH AI Assist is the first AI drug development tool to be qualified by the FDA. The tool is designed to ...